Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Sunday, November 23 2014 5:42pm ET - U.S. Markets Closed.
Industry Center
Industry Center > > UCB S.A. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
UCB S.A. Company Profile
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS). The company manufacturers prescription drugs to treat Crohn's disease, epilepsy, and Parkinson's disease. UCB's top products include Cimzia for Crohn's disease,Vimpat to treat epilepsy, and Neupro for Parkinson's disease. The company also makes allergy blockbuster Zyrtec. UCB has operations in nearly 30 countries, and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include AstraZeneca and Novartis. Financière de Tubize owns a majority stake in UCB.
Headlines for UCB S.A.
UCB to Sell Generics Business, Focus on Core Segments
- Mon Nov 10
Belgium's UCB to sell generics unit for 964 million pounds
- Fri Nov 7
Pitch report: Zahur Ahmed Chowdhury Stadium
- Tue Nov 11
Pharma Industry Outlook: M&A, Licensing Abound
- Wed Nov 19
Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3?
- Wed Nov 12
Contact Information
Address: Allée de la Recherche 60
1070 Brussels, Belgium
Phone:+32-2-559-99-99--
Fax:+32-2-559-99-00
Financial Highlights
Fiscal Year End:December
Revenue (2013):4695.60 M
Revenue Growth (1 yr):2.60%
Employees (2013):8,732
Employee Growth (1 yr):(-3.50%)
Key People
Chairman: Gerhard N. Mayr
Chief Executive Officer and Chairman of the Executive Commit: Roch F. Doliveux
Executive Vice President and Chief Financial Officer: Detlef Thielgen
Industry Information
Sector:
Industry:
Top Competitors
Cephalon, Inc.
Johnson & Johnson (jnj)
Pfizer Inc. (pfe)
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?